The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait?
Authors:
- 1 December 2020
- journal article
- review article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 51 (4) , 1152-1156
Abstract
Purpose HCC is a complex disease that is diagnosed in advanced stage and on the background of cirrhosis. Locoregional therapies provide sufficient downstaging to enable patients suitable for radical procedures such liver transplantation. However, the interval between locoregional therapies and definitive therapy is still controversial. We performed a review of literature to evaluate the role of waiting period between locoregional therapies and liver transplantation or resection from the perspective of cure and recurrence rates. Methods Thorough literature search was performed to evaluate the role of locoregional therapy and the interval to definitive therapies for the treatment of hepatocellular cancer. Results Usually, small tumors with lower tumor burden, in other words, tumors within Milan criteria, can be transplanted with an acceptable overall and disease-free survival. However, treating patients with locally advanced tumors is currently a matter of extensive research. Currently, locoregional therapies are applied to downstage the patients. However, the duration of waiting is a crucial point that needs further research. There is a consensus that the waiting interval between down-staging and transplantation should be no less than 3 months. This is important for selection of favorable tumor biology as well as from the point of antitumor immune response. Conclusion Currently, there are no surrogate markers for surveillance of response to locoregional therapies as well as the antitumor immune response that develops as a result of down-staging.Keywords
This publication has 51 references indexed in Scilit:
- Liver transplantation for hepatocellular carcinoma: Where do we stand?World Journal of Gastroenterology, 2019
- Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscapeHepatoma Research, 2019
- Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasionJournal of Hepatology, 2018
- Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It?Transplantation Proceedings, 2018
- The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation studyHepatology, 2016
- Evaluation of Total Tumor Volume and Pretransplantation α-Fetoprotein Level as Selection Criteria for Liver Transplantation in Patients With Hepatocellular CancerTransplantation Proceedings, 2013
- Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysisThe Lancet Oncology, 2009
- Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinomaBritish Journal of Surgery, 2007
- Hepatocellular carcinoma: Current management and future trendsGastroenterology, 2004
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisNew England Journal of Medicine, 1996